CD22 and Burkitt lymphoma: One clinical trial (ChiCTR1800014457) recently revealed prolonged and significant efficiency and safety of sequential CD19-CD22-CD20 CAR-T therapy in pediatric patients suffering relapsed/refractory Burkitt lymphoma (r/r BL), even in patients with central nervous system (CNS) involvement [37, 38].